Effect of short-term thiamine supplementation on oxidative stress, inflammation, exercise capacity and prognosis in chronic heart failure: a randomized clinical trial Thiamine in the treatment of CHF.

Main Article Content

Like Geng https://orcid.org/0000-0002-1825-0097
Sanjun He
Luzhao Wang https://orcid.org/0000-0002-1825-0097
Qun Dang https://orcid.org/0000-0002-1825-0097
Fang Wang https://orcid.org/0000-0002-1825-0097
Guo Lv https://orcid.org/0000-0002-1825-0097


Thiamine; Chronic heart failure; Oxidative stress; Inflammation; Exercise capacity; Rehospitalization.


Background and aim: Thiamine has known antioxidative and anti-inflammatory effects. However, the effectiveness of thiamine supplementation and clinical outcome in chronic heart failure (CHF) are unclear. Therefore, this study focuses on evaluating the effect of short-term thiamine supplementation on oxidative stress, inflammation, exercise capacity, and predicts the ability of rehospitalization within 30-day in patients with CHF.

Methods: Sixty hospitalized patients with CHF were randomly divided into two groups. Both groups received conventional anti-heart failure treatment, but the thiamine group (n=30) received thiamine (100 mg/day) by intramuscular injection for 1 week, while the control group (n=30) did not do it. Serum thiamine, malondialdehyde (MDA), superoxide dismutase (SOD), high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), pro-B-type natriuretic peptide (pro-BNP) levels and 6-minute walking distance (6MWD) were detected in the two groups before and after the treatment, and all the participants were followed-up for 30-day after discharge.

Results: After 1 week of treatment, serum thiamine levels were significantly decreased in control group compared with baseline (p<0.05), and the SOD levels and 6MWD in the thiamine group were significantly increased compared with the control group (p<0.05). Serum thiamine levels in the thiamine group were independent determinants of serum SOD levels (standardized coefficient=0.4, p=0.022) and 6MWD (standardized coefficient=0.518, p=0.004) after thiamine supplementation. Serum thiamine levels before discharge (hazard ratio [HR], 0.957, 95% confidence interval [CI], 0.924 to 0.992; p=0.016) was independently related to the rehospitalization within 30-day.

Conclusions: In conclusion, short-term thiamine supplementation could improve oxidative stress and exercise capacity, and serum thiamine levels before discharge was an independent predictor of rehospitalization within 30-day. Meanwhile, furosemide could reduce serum thiamine levels in patients with CHF.


Download data is not yet available.
Abstract 35 | PDF Downloads 162


1. Jones NR, Roalfe AK, Adoki I, Hobbs FDR, Taylor CJ. Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis. Eur J Heart Fail. 2019; 21: 1306-25.
2. Aimo A, Castiglione V, Borrelli C, et al. Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies. Eur J Prev Cardiol. 2020; 27: 494-510.
3. Eshak ES, Arafa AE. Thiamine deficiency and cardiovascular disorders. Nutr Metab Cardiovasc Dis. 2018; 28: 965-72.
4. Goel A, Kattoor AJ, Mehta JL. Thiamin therapy for chronic heart failure: is there any future for this vitamin? Am J Clin Nutr. 2019; 110: 1270-71.
5. Katta N, Balla S, Alpert MA. Does Long-Term Furosemide Therapy Cause Thiamine Deficiency in Patients with Heart Failure? A Focused Review. Am J Med. 2016; 129: 753 e7-53 e11.
6. Yue QY BB, Lindström B, Nyquist O. No difference in blood thiamine diphosphate levels between Swedish Caucasian patients with congestive heart failure treated with furosemide and patients without heart failure. J Intern Med. 1997; 242: 491-95.
7. Hanninen SA, Darling PB, Sole MJ, Barr A, Keith ME. The prevalence of thiamin deficiency in hospitalized patients with congestive heart failure. J Am Coll Cardiol. 2006; 47: 354-61.
8. Gioda CR, de Oliveira Barreto T, Primola-Gomes TN, et al. Cardiac oxidative stress is involved in heart failure induced by thiamine deprivation in rats. Am J Physiol Heart Circ Physiol. 2010; 298: H2039-45.
9. Okai Y H-OK, Sato EF, Konaka R, Inoue M. Potent radical-scavenging activities of thiamin and thiamin diphosphate. J Clin Biochem Nutr 2007; 40: 42-8.
10. Ayoub KF, Pothineni NVK, Rutland J, Ding Z, Mehta JL. Immunity, Inflammation, and Oxidative Stress in Heart Failure: Emerging Molecular Targets. Cardiovascular Drugs and Therapy. 2017; 31: 593-608.
11. Karuppagounder SS, Shi Q, Xu H, Gibson G E. Changes in inflammatory processes associated with selective vulnerability following mild impairment of oxidative metabolism. Neurobiol Dis. 2007; 26: 353-62.
12. Liu D, Ke Z, Luo J. Thiamine Deficiency and Neurodegeneration: the Interplay Among Oxidative Stress, Endoplasmic Reticulum Stress, and Autophagy. Mol Neurobiol. 2017; 54: 5440-48.
13. Abdou E, Hazell AS. Thiamine deficiency: an update of pathophysiologic mechanisms and future therapeutic considerations. Neurochem Res. 2015; 40: 353-61.
14. Lynch PL, Young IS. Determination of thiamine by high-performance liquid. J Chromatogr A. 2000; 881: 267-84.
15. Manzetti S, Zhang J, van der Spoel D. Thiamin function, metabolism, uptake, and transport. Biochemistry. 2014; 53: 821-35.
16. Dey S, DeMazumder D, Sidor A, Brian Foster D, O’Rourke B. Mitochondrial ROS Drive Sudden Cardiac Death and Chronic Proteome Remodeling in Heart Failure. Circ Res. 2018; 123: 356-71.
17. Li JM, Gall NP, Grieve DJ, Chen M, Shah AM. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension. 2002; 40: 477-84.
18. Zhao Y, Pan X, Zhao J, Wang Y, Peng Y, Zhong C. Decreased transketolase activity contributes to impaired hippocampal neurogenesis induced by thiamine deficiency. J Neurochem. 2009; 111: 537-46.
19. Alam SS, Riaz S, Waheed Akhtar M. Effect of high dose thiamine therapy on activity and molecular aspects of transketolase in Type 2 diabetic patients. African Journal of Biotechnology. 2011; 10:17305-16.
20. Riyapa D, Rinchai D, Muangsombut V, et al. Transketolase and vitamin B1 influence on ROS-dependent neutrophil extracellular traps (NETs) formation. PLoS One. 2019; 14: 1-17.
21. Ahmed LA, Hassan OF, Galal O, Mansour DF, El-Khatib A. Beneficial effects of benfotiamine, a NADPH oxidase inhibitor, in isoproterenol-induced myocardial infarction in rats. PLoS One. 2020; 15:1-17.
22. Sarandol E, Tas S, Serdar Z, Dirican M. Effects of thiamine treatment on oxidative stress in experimental diabetes. Bratisl Lek Listy. 2020; 121: 235-41.
23. Radonjic T, Rankovic M, Ravic M, et al. The Effects of Thiamine Hydrochloride on Cardiac Function, Redox Status and Morphometric Alterations in Doxorubicin-Treated Rats. Cardiovasc Toxicol. 2020; 20: 111-20.
24. González-Ortiz M, Martínez-Abundis E, Robles-Cervantes JA, Ramírez-Ramírez V, Ramos-Zavala MG. Effect of thiamine administration on metabolic profile, cytokines and inflammatory markers in drug-naive patients with type 2 diabetes. Eur J Nutr. 2011; 50: 145-9.
25. Amirani E, Aghadavod E, Shafabakhsh R, et al. Anti-inflammatory and antioxidative effects of thiamin supplements in patients with gestational diabetes mellitus. J Matern Fetal Neonatal Med. 2020: 1-6.
26. Smithline HA, Donnino M, Blank FSJ, et al. Supplemental thiamine for the treatment of acute heart failure syndrome: a randomized controlled trial. BMC Complementary and Alternative Medicine. 2019;19:1-11.
27. Keith M, Quach S, Ahmed M, et al. Thiamin supplementation does not improve left ventricular ejection fraction in ambulatory heart failure patients: a randomized controlled trial. Am J Clin Nutr. 2019; 110: 1287-95.
28. Yamada Y KY, Akaoka M, Watanabe M, et al. Thiamine treatment preserves cardiac function against ischemia injury via maintaining mitochondrial size and ATP levels. J Appl Physiol 2021; 130: 26-35.
29. Li X, Luan H, Zhang H, et al. Associations between early thiamine administration and clinical outcomes in critically ill patients with acute kidney injury. The British journal of nutrition. 2021: 1-9.
30. Ao M YK, Ohta J, Abe Y, et al. Possible involvement of thiamine insufficiency in heart failure in the institutionalized elderly. J Clin Biochem Nutr. 2019; 64: 239-42.
31. Seligmann H, Halkin H, Rauchfleisch S, et al. Thiamine deficiency in patients with congestive heart failure receiving long-term furosemide therapy: A pilot study. Am J Med. 1991; 91: 151-55.
32. Whitfield KC, Bourassa MW, Adamolekun B, et al. Thiamine deficiency disorders: diagnosis, prevalence, and a roadmap for global control programs. Ann N Y Acad Sci. 2018; 1430: 3-43.
33. Zeng L, Wu X, Liu L, Xu L, Kuang H, Xu C. Production of a monoclonal antibody for the detection of vitamin B1 and its use in an indirect enzyme-linked immunosorbent assay and immunochromatographic strip. J Mater Chem B. 2020; 8: 1935-43.